This section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentHIGHLIGHTS
Sign In or Create an Account
or View more offersArticle content
- H1 2026 revenues of €1.89 billion, up +3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area
- Continued investment in innovation with €426 million invested in R&D (22.5% of sales)
- Completed strategic investment for treatment of hereditary angioedema (HAE) with acquisition of KalVista Pharmaceuticals
- EBITDA continues to remain close to 30%, reflecting continued strong profitability and disciplined resource allocation
- Recent Economic Footprint study highlights Chiesi’s contribution to economic development, supporting 56,488 jobs globally, generating €6.0 billion in GDP impact and €2.0 billion in taxes and public revenues worldwide
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
PARMA, Italy — Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 (“H1 2026”).
Article contentArticle contentPerformance across therapeutic areas and regions
Article content
Chiesi reported revenues of
Article content€1.89 billionArticle content
, representing growth of
Article content +3.6% at constant exchange rates (CER)Article content
compared with H1 2025. These results do not include the impact of the recent acquisition of KalVista Pharmaceuticals.
Article content
The Group’s growth is supported by continued expansion of its global rare diseases area (+€45m; +9.9% @CER), and sustained performance in neonatology and specialty care therapeutic areas (+6.5% @CER). The respiratory health area remains broadly stable (-0.8% @CER) fueled by the strong growth in our inhaled triple therapy portfolio.
Article content
Driven by the ongoing execution of its international growth strategy, Chiesi continued to expand its presence in key markets, with particularly strong momentum in the United States (+9.6% @CER), while maintaining resilient performance across Europe (+0.9% @CER) and a continuous development of the remaining geographies (+5.5% @CER). EBITDA margin was 29.4%, reflecting continued strong profitability, disciplined resource allocation and operational focus. The Group also maintained solid cash generation from operations, enabling continued investment in its research pipeline, manufacturing capabilities, and strategic acquisitions.
Article contentContinued commitment to innovation
Article content
The focus on innovation remains central to Chiesi’s strategy. During the first half of 2026, the Group invested
Article content€426 millionArticle content
in Research & Development, representing approximately
Article content22.5% of revenuesArticle content
.
Article content
Investments were focused on advancing the pipeline across respiratory health, rare diseases and specialty care, while also supporting the development of the Group’s Carbon Minimal Inhaler (CMI) platform and strengthening the industrial capabilities required to support its future rollout. This included the strategic partnership with Bespak, aimed at delivering lower carbon inhaled therapies through CMIs at scale, without compromising clinical choice or continuity of care for patients.
Article content
During the first half of the year, Chiesi also completed the acquisition of KalVista Pharmaceuticals, a US-based pharmaceutical company with a differentiated oral, on demand treatment for hereditary angioedema (HAE), further strengthening its global rare disease platform and pipeline in areas of high unmet medical need.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article contentCreating positive impact beyond healthcare: Chiesi’s Economic Footprint
Article content
Chiesi’s impact extends well beyond the healthcare solutions it delivers to patients. According to its recent Economic Footprint assessment conducted with PwC Italy (part of an international professional services network), in 2025 the Group generated approximately
Article content€6 billion in total GDP worldwideArticle content
, supported
Article content56,488 jobsArticle content
, and contributed nearly
Article content€2 billion in taxes and public revenuesArticle content
across the countries in which it operates.
Article content
As a European-headquartered company with innovation deeply rooted across the region, Chiesi generated €4.1 billion in total GDP across Europe, supported almost 30,000 jobs and contributed approximately €1.4 billion in taxes and public revenues. The study also found that Europe accounted for 78% of Chiesi’s global R&D investment and 60% of all suppliers engaged by the Group, highlighting the region’s central role in driving innovation, employment and economic growth.
Article content
At the same time, Chiesi continues to expand its contribution in key international markets, generating more than €1.1 billion in GDP impact in the U.S. while supporting almost 4,000 jobs in the country. It also contributes €800 million in GDP impact across China, Brazil, Australia, Mexico and rest of the world, and more than 22,000 jobs across these markets.
Article content
These findings demonstrate Chiesi’s long-standing commitment to strengthening the overall healthcare ecosystem and creating value for patients, healthcare systems, local communities and economies across the world.
Article content
Jean Marc Bellemin, CFO and Interim CEO of Chiesi Group, commented:
Article content
“Our first-half results for 2026 reflect the resilience of our strategy and the strength of our global footprint. As we continue to deliver a solid performance, we remain focused on innovation, sustainable growth, and creating long-term value for patients, society and the environment. The acquisition of KalVista further strengthens our position in rare diseases and expands our presence in the U.S., while our Economic Footprint study illustrates Chiesi’s broader contribution to the economies and communities in which we operate. We remain focused on combining sustainable growth with continued innovation and long-term value creation for patients and society.”
Article contentAbout Chiesi Group
Article content
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.